Solid Biosciences (SLDB) said Wednesday it is teaming up with Mayo Clinic to advance an adeno-associated virus gene therapy platform to develop therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies.
The genetic medicine company said it will receive exclusive licenses to the Mayo Clinic's suppression and replacement gene therapy platform and to six cardiac gene therapy programs developed using the platform.
Solid said its AAV capsids and manufacturing capabilities will be used by the programs to suppress and replace genes implicated in potentially life-threatening genetic heart diseases.
Mayo Clinic will have the research and development responsibilities for the gene therapy candidates up to investigational new drug-enabling studies, at which point Solid can choose to continue the development of commercialization of each program.
Shares of Solid Biosciences were more than 6% higher in premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。